These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 21926484

  • 1. Effectiveness and safety of citalopram in hospitalized adolescents with major depression: a preliminary, 8-week, fixed-dose, open-label, prospective study.
    Shoval G, Nahshoni E, Gothelf D, Manor I, Golobchik P, Zemishlany Z, Weizman A, Zalsman G.
    Clin Neuropharmacol; 2011; 34(5):182-5. PubMed ID: 21926484
    [Abstract] [Full Text] [Related]

  • 2. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.
    Amsterdam JD, Shults J, Rutherford N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan 01; 32(1):100-6. PubMed ID: 17804135
    [Abstract] [Full Text] [Related]

  • 3. Citalopram and suicidality in adult major depression and anxiety disorders.
    Pedersen AG.
    Nord J Psychiatry; 2006 Jan 01; 60(5):392-9. PubMed ID: 17038305
    [Abstract] [Full Text] [Related]

  • 4. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R, da Silva Telles RM, Alves TC, Andrei AM, Rays J, Iosifescu DV, Wajngarten M.
    Contemp Clin Trials; 2009 May 01; 30(3):205-11. PubMed ID: 19470312
    [Abstract] [Full Text] [Related]

  • 5. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B, Andersen HF, Dolberg OT.
    Depress Anxiety; 2007 May 01; 24(1):53-61. PubMed ID: 16937393
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
    Kim JE, Yoon SJ, Kim J, Jung JY, Jeong HS, Cho HB, Shin E, Lyoo IK, Kim TS.
    Int J Clin Pract; 2011 Mar 01; 65(3):323-9. PubMed ID: 21314870
    [Abstract] [Full Text] [Related]

  • 7. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun 01; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov 01; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 9. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
    Olié JP, Tonnoir B, Ménard F, Galinowski A.
    Depress Anxiety; 2007 Nov 01; 24(5):318-24. PubMed ID: 17041922
    [Abstract] [Full Text] [Related]

  • 10. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M.
    Curr Med Res Opin; 2006 Jul 01; 22(7):1331-41. PubMed ID: 16834832
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study.
    Brown ES, Vigil L, Khan DA, Liggin JD, Carmody TJ, Rush AJ.
    Biol Psychiatry; 2005 Dec 01; 58(11):865-70. PubMed ID: 15993860
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S, Bodlund O, Agren H.
    J Clin Psychopharmacol; 2006 Apr 01; 26(2):121-7. PubMed ID: 16633139
    [Abstract] [Full Text] [Related]

  • 13. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec 01; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 14. A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury.
    Rapoport MJ, Mitchell RA, McCullagh S, Herrmann N, Chan F, Kiss A, Feinstein A, Lanctôt KL.
    J Clin Psychiatry; 2010 Sep 01; 71(9):1125-30. PubMed ID: 20441723
    [Abstract] [Full Text] [Related]

  • 15. First episode of major depressive disorder and vascular factors in coronary artery disease patients: Baseline characteristics and response to antidepressant treatment in the CREATE trial.
    Habra ME, Baker B, Frasure-Smith N, Swenson JR, Koszycki D, Butler G, van Zyl LT, Lespérance F.
    J Psychosom Res; 2010 Aug 01; 69(2):133-41. PubMed ID: 20624511
    [Abstract] [Full Text] [Related]

  • 16. Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial.
    Park HY, Lee BJ, Kim JH, Bae JN, Hahm BJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar 30; 36(2):318-23. PubMed ID: 22142651
    [Abstract] [Full Text] [Related]

  • 17. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES, Howard C, Khan DA, Carmody TJ.
    Psychosomatics; 2012 Mar 30; 53(1):75-80. PubMed ID: 22221724
    [Abstract] [Full Text] [Related]

  • 18. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L, Andersen HF, Reines EH.
    Curr Med Res Opin; 2005 Oct 30; 21(10):1659-68. PubMed ID: 16238906
    [Abstract] [Full Text] [Related]

  • 19. Citalopram in the treatment of women with chronic pelvic pain: an open-label trial.
    Brown CS, Franks AS, Wan J, Ling FW.
    J Reprod Med; 2008 Mar 30; 53(3):191-5. PubMed ID: 18441724
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.
    von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hultén A.
    J Clin Psychopharmacol; 2006 Jun 30; 26(3):311-5. PubMed ID: 16702897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.